820 related articles for article (PubMed ID: 27056738)
1. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
[TBL] [Abstract][Full Text] [Related]
2. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation.
Oldgren J; Hijazi Z; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Granger CB; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Wallentin L;
Circulation; 2016 Nov; 134(22):1697-1707. PubMed ID: 27569438
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
[TBL] [Abstract][Full Text] [Related]
4. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Yusuf S; Granger CB; Siegbahn A; Wallentin L;
Eur Heart J; 2018 Feb; 39(6):477-485. PubMed ID: 29069359
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Alings M; De Caterina R; Eikelboom JW; Ezekowitz MD; Held C; Huber K; Hylek EM; Granger CB; Lopes RD; Vinereanu D; Siegbahn A; Wallentin L
JAMA Netw Open; 2020 Sep; 3(9):e2015943. PubMed ID: 32936298
[TBL] [Abstract][Full Text] [Related]
6. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
[TBL] [Abstract][Full Text] [Related]
7. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas.
Pol T; Hijazi Z; Lindbäck J; Alexander JH; Bahit MC; De Caterina R; Eikelboom JW; Ezekowitz MD; Gersh BJ; Granger CB; Hylek EM; Lopes R; Siegbahn A; Wallentin L
Open Heart; 2021 Mar; 8(1):. PubMed ID: 33741689
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
10. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.
Hijazi Z; Lindbäck J; Alexander JH; Hanna M; Held C; Hylek EM; Lopes RD; Oldgren J; Siegbahn A; Stewart RA; White HD; Granger CB; Wallentin L;
Eur Heart J; 2016 May; 37(20):1582-90. PubMed ID: 26920728
[TBL] [Abstract][Full Text] [Related]
11. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldan V; Vicente V; Valdés M; Marín F; Lip GYH
Thromb Haemost; 2017 Oct; 117(10):1848-1858. PubMed ID: 28799620
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L;
Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
Vinereanu D; Stevens SR; Alexander JH; Al-Khatib SM; Avezum A; Bahit MC; Granger CB; Lopes RD; Halvorsen S; Hanna M; Husted S; Hylek EM; Mărgulescu AD; Wallentin L; Atar D
Eur Heart J; 2015 Dec; 36(46):3268-75. PubMed ID: 26371113
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
Senoo K; Proietti M; Lane DA; Lip GY
Am J Med; 2016 Jun; 129(6):600-7. PubMed ID: 26482233
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
[TBL] [Abstract][Full Text] [Related]
16. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial.
Rao MP; Vinereanu D; Wojdyla DM; Alexander JH; Atar D; Hylek EM; Hanna M; Wallentin L; Lopes RD; Gersh BJ; Granger CB;
Am J Med; 2018 Mar; 131(3):269-275.e2. PubMed ID: 29122636
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
[TBL] [Abstract][Full Text] [Related]
19. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
[TBL] [Abstract][Full Text] [Related]
20. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
